Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMWVBGD)

Drug Name

CR-2093 Drug Info

Synonyms

CR-2093; CR 2093; 136374-73-7; AC1L303W; 4-(3-Chlorobenzamido)-5-(3,3-dimethylbutylamino)-5-oxopentanoic acid; (R)-4-(3-Chlorobenzoylamino)-5-oxo-5-(3,3-dimethylbutylamino)valeric acid; (4R)-4-[(3-chlorobenzoyl)amino]-5-(3,3-dimethylbutylamino)-5-oxopentanoic acid; Pentanoic acid, 4-((3-chlorobenzoyl)amino)-5-((3,3-dimethylbutyl)amino)-5-oxo-, (R)-

Indication

Disease Entry	ICD 11	Status	REF
Intestine cancer	2C0Z	Discontinued in Phase 1	[1]

Cross-matching ID

PubChem CID: 131954
CAS Number: CAS 136374-73-7
TTD Drug ID: DMWVBGD

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Gastrin/cholecystokinin type B receptor (CCKBR)	TTVFO0U	GASR_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule	Molecule Type	Gene Name	Liver	Colon	Kidney	Small Intestine
Gastrin/cholecystokinin type B receptor (CCKBR)	DTT	CCKBR	5.618	5.638	5.466	6.002

Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Intestine cancer

ICD Disease Classification

2C0Z

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Gastrin/cholecystokinin type B receptor (CCKBR)	DTT	CCKBR	6.53E-01	1.00E-03	4.05E-03

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800001442)
2	Inhibitory effects of the gastrin receptor antagonist CR2093 on basal, gastrin-stimulated and growth factor-stimulated growth of the rat pancreatic cell line AR42J. Anticancer Drugs. 1994 Oct;5(5):591-7.